Shire HGT Announces Approval for Elaprase
In July 2006 the U.S. Food and Drug Administration (FDA) announced approval of Elaprase, the first
treatment for individuals with MPS II. Elaprase (idursulfase) is an enzyme replacement therapy from
Shire Human Genetic Therapies. Elaprase is designed to replace iduronate-2-sulfatase (I2S), the enzyme
that is deficient or absent in people with MPS II. Elaprase has been shown to improve walking capacity
in these individuals. Elaprase is available by prescription only. To learn more, please visit
www.elaprase.com for full prescribing information.
OnePath is the product support center that can help you with many aspects of Elaprase therapy. For
access to a wide range of product services and support, please call OnePathat 1-866-888-0660 or
visit OnePath.com. Case managers are available Monday through Friday, 8:30 a.m. to 8:00 p.m. Eastern
Time to offer resources and support and determine your specific needs.
Shire Human Genetic Therapies, is one of the world’s leading speciality biopharmaceutical companies
located in Cambridge, MA, with a major focus on developing products for the treatment of rare diseases. Shire HGT is developing an enzyme replacement therapy for patients with MPS IIIA administered into the cerebrospinal fluid. That clinical trial is currently being conducted in the U.K. Shire HGT is also sponsoring a natural history study for MPS IIIA.